Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

advertisement

advertisement

Member Advantages

Residents and Fellows Committe Essay Contest Submissions Due January 12
Medical students, residents and fellows are invited to submit their essays for the 9th annual essay contest. Essays are due January 12, 2026. This year's topic is "Beyond the Chart: Patients as Teachers." Learn More
APP of the Year Nominations Close January 12
Nominate an outstanding Advanced Practice Provider (APP) who is making a significant impact in patient care, mentoring colleagues, or demonstrating exceptionl leadership. Apply Now
Explore the 2025 AUA Year in Review
We invite you to take a moment to explore the many accomplishments we made this year serving our 25,000 members around the world. Explore Now
Free Webcast Designed for APPs
Managing Male OAB: Update for the APP provides Advanced Practice Providers with practical updates on the latest strategies for managing Overactive Bladder. Stream Now

Latest from the Journals

JU | January 2026

Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte–Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer

In QUILT-3.032, the efficacy of interleukin-15 receptor agonist, nogapendekin alfa inbakicept (NAI), in combination with bacillus Calmette-Guérin (BCG) for BCG-unresponsive high-grade papillary-only nonmuscle-invasive bladder cancer was assessed. In this study, we report the 36-month follow-up among participants with BCG-unresponsive papillary disease (cohort B).

View Now